Axendia, Inc.

📅 Just one week to go! Axendia’s own Daniel Matlis will take the stage at the Honeywell | Life Sciences World Tour 2025 to share his insights on how innovation and disruption are shaping the future of Life Sciences. This can’t-miss session is designed for leaders navigating the complex intersection of business, technology, regulation, and patient outcomes. 👉 Register here: https://lnkd.in/ebuumu2r #HLS25 Gary Iszatt Martin Dowdall, Shawn Opatka, Steve McCarthy, Martin Magazzolo, Cynthia Babb, Bart Reitter, Fabrizio Maniglio, Chris Peters, Kelly Doering, Sandra Rodriguez, Eric M. Luyer Axendia, Inc.

3 Strategic Must-Dos to Navigate Tariff Disruption. Read the article in Life Science Panorama

Our very own Consulting Industry Analyst Kelly Doering represented our team at the 2025 The Stellix Group Aspire event! Keep an eye out for Kelly’s event brief, where she’ll unpack the top takeaways and emerging themes! #StellixAspire2025

We’re proud to share that Daniel Matlis will deliver the Analyst Keynote at the 2025 Honeywell Life Sciences World Tour. In a rapidly evolving industry, Dan will share critical insights on how innovation and disruption are reshaping the global Life Sciences landscape. This is a can’t-miss session for leaders navigating the complex interplay between business, technology, regulation, and patient outcomes. 📅 Date: April 22, 2025 🕥 Time: 10:15 AM ET 📍 Location: Orlando, FL 👉 Register here: https://lnkd.in/ebuumu2r #HLS25 Honeywell | Life Sciences Gary Iszatt Martin Dowdall, Shawn Opatka, Steve McCarthy, Martin Magazzolo, Cynthia Babb, Bart Reitter, Fabrizio Maniglio, Chris Peters, Kelly Doering, Sandra Rodriguez, Eric M. Luyer

Happy 45th Anniversary, Amgen! We’re grateful for the privilege of collaborating with Amgen’s visionary teams on initiatives that bridge science, technology, and compliance. We’re proud to support your efforts to deliver high-quality, life-changing therapies—and to contribute to a culture that values innovation, operational excellence, and, above all, patients. Here’s to 45 years of impact, and an exciting road ahead! 

We are grateful for the opportunity to advise Honeywell | Life Sciences on the TrackWise Manufacturing Platform. “In the face of economic pressures, shifting market demands, and evolving regulatory requirements, the Life Sciences industry is at an inflection point,” said Daniel Matlis, President and Founder at Axendia. “Industry leaders must seize the opportunity to transform and leverage technological advancements to unify digital quality and manufacturing. Embracing modern technologies, Industry can significantly enhance operational effectiveness, improve product quality, streamline regulatory compliance, and accelerate time to market.” This effort highlighted the need to break down silos for improve visibility, flexibility, and efficiency, enhancing resilience in response to market changes. The Biopharma industry continues to invest in innovation aimed at improving patient outcomes. At Axendia, we remain committed to providing independent, research-based strategic advice that empowers organizations to thrive amidst disruption and complexity. Together, we can turn challenges into opportunities for success. 🚀 Grateful to Gary Iszatt, Martin Dowdall,  Shawn Opatka,  Steve McCarthy, Martin Magazzolo, Cynthia Babb, Bart Reitter, Fabrizio Maniglio, Chris Peters Mónica V. M. Sandra Rodriguez Kelly Doering Eric M. Luyer

Are you going to be at the The Stellix Group Aspire event on April 10th in Foxborough, MA? As you’re planning your day, be sure to keep an eye out for Kelly Doering, Consulting Industry Analyst with Axendia. We’re excited to see old friends and meet some new. Please reach out ahead of time if you’d like to meet! Leave a note in the comments or DM Kelly directly. https://lnkd.in/eMcYd947 Daniel Matlis Mónica V. M. Sandra Rodriguez

We are incredibly grateful for the opportunity to advise Siemens in shaping the Enterprise Recipe Management (ERM) solution from its inception. This effort provided valuable insights into the importance of bridging the gap between Research, Development, and Manufacturing—an essential step in breaking down data silos, fostering knowledge sharing across organizations, and driving improvements in resilience. Adopting these strategies enables organizations to build resilience and accelerate both time to market and time to volume, critical factors in today’s fast-paced Biopharma landscape. Improved collaboration between Research, Development, and Manufacturing plays a key role in enabling Biopharma companies to standardize, scale, and improve operations while maintaining flexibility and ensuring regulatory compliance. The Biopharma industry continues to lead in innovation, and it’s been an honor to contribute toward efforts that support its success. At Axendia, we remain committed to providing independent, research-based strategic advice that empowers organizations to thrive amidst disruption and complexity. Together, we can turn challenges into opportunities for success. 🚀 We are especially grateful to Todd Lybrook, PMP, Jim Thompson, Andrew Whytock, Michel Claes, Ivo Backx, Arnaud Lassalle, Stefan Krauss, Julita Panek, Gerry Keane, Patrick Bossuyt, Vincent Boudou, Jennifer Petrosky, Kim M. Edwards Daniel Matlis Sandra Rodriguez Mónica V. M. Kelly Doering Eric Luyer

🚨 #AI is redefining Quality Management—are you leading the change or reacting to it? Flex's Garth Conrad and Axendia's Sandra Rodriguez collaborated on an article looking the seismic shift that is happening in the quality landscape. What began with simple AI prompts has evolved into systems capable of independent decision-making. With each stage of maturity, we see fewer errors, less human intervention, and more strategic value. Forward-thinking companies aren’t waiting for guidance—they’re helping shape it. By engaging with regulators and standards bodies, they're building the foundations for responsible AI governance in Life Sciences. 💡The truth? Strategic adoption beats reactive implementation every time. There’s also a hidden cost in standing still. Outdated, manual, and error-prone processes are expensive to maintain and even more expensive to scale. Organizations that delay investment in AI-driven quality risk falling behind on compliance, cost control, and competitiveness. Read the full article here and join in on the conversation: https://lnkd.in/dErAxdnR

𝗧𝗵𝗲 𝗜𝗺𝗽𝗮𝗰𝘁 𝗼𝗳 𝗧𝗮𝗿𝗶𝗳𝗳𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆. Tariffs have emerged as a key factor affecting the medical device and biopharmaceutical industries. C𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝘁𝗵𝗮𝘁 𝗽𝗿𝗼𝗮𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗮𝗱𝗷𝘂𝘀𝘁 𝘁𝗵𝗲𝗶𝗿 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗰𝗮𝗻 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻 𝘁𝗵𝗲𝗺𝘀𝗲𝗹𝘃𝗲𝘀 𝗳𝗼𝗿 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝘀𝘂𝗰𝗰𝗲𝘀𝘀.  Read this article learn find out how: https://lnkd.in/ehFy7Jmu